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Abstract
Aims/hypothesis Obesity is associated with glucose intoler-
ance and insulin resistance and is closely linked to the increas-
ing prevalence of type 2 diabetes. In mouse models of diet-
induced obesity (DIO) and type 2 diabetes, an increased fat
intake results in adipose tissue expansion and the secretion of
proinflammatory cytokines. The innate immune system not
only plays a crucial role in obesity-associated chronic low-
grade inflammation but it is also proposed to play a role in
modulating energy metabolism. However, little is known
about how the modulation of metabolism by the immune sys-
tem may promote increased adiposity in the early stages of
increased dietary intake. Here we aimed to define the role of
type I IFNs in DIO and insulin resistance.
Methods Mice lacking the receptor for IFN-α (IFNAR−/−)
and deficient in plasmacytoid dendritic cells (pDCs) (B6.E2-
2fl/fl.Itgax-cre) were fed a diet with a high fat content or normal
chow. The mice were analysed in vivo and in vitro using
cellular, biochemical and molecular approaches.
Results We found that the development of obesity was inhibited
by an inability to respond to type I IFNs. Furthermore, the
development of obesity and insulin resistance in this model
was associated with pDC recruitment to the fatty tissues and
liver of obese mice (a 4.3-fold and 2.7-fold increase, respec-
tively). Finally, we demonstrated that the depletion of pDCs
protects mice from DIO and from developing obesity-
associated metabolic complications.
Conclusions/interpretation Our results provide genetic evi-
dence that pDCs, via type I IFNs, regulate energy metabolism
and promote the development of obesity.
Keywords Adipose tissue . Obesity . pDCs . Type I
interferons
Abbreviations
AT Adipose tissue
BAT Brown adipose tissue
DC Dendritic cell
DIO Diet-induced obesity
FVD Fixable viability dye
HFD High-fat diet
IFNAR IFN-α receptor
MCP-1 Monocyte chemoattractant protein-1
ND Normal diet
pDC Plasmacytoid dendritic cell
SAT Subcutaneous adipose tissue
SVF Stromal vascular fraction
TLR Toll-like receptor
VAT Visceral adipose tissue
Introduction
Obesity is recognised as a medical condition characterised by
the accumulation of excess body fat and is associated with a
chronic state of low-grade inflammation. Low-grade inflam-
mation in the adipose tissue (AT) involving both the adaptive
and the innate immune system is reflected by a cytokine-
induced acute-phase response, including elevated levels of
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TNF-α, IL-6 and C-reactive protein as part of an immune
response of both innate and adaptive origin. A key role in
the development of metabolic abnormalities has been assigned
to M1-polarised macrophages that accumulate in the AT to-
gether with other immune cells [1–3].
A role for dendritic cells (DCs) in promoting macrophage
infiltration to AT in obesity has been suggested [4], and an
increased frequency of dysfunctional DCs in obese mice and
humans supports this notion [4–6]. However, a full under-
standing of the role of DCs in this process is still lacking.
The Toll-like receptor (TLR)-4 (expressed on the surface of
macrophages, DCs and other immune and non-immune cells)
has been reported to respond to the increased levels of endog-
enous lipids found in obese individuals [7]. In line with this,
lipid-lowering agents acting through a TLR-4-mediated
mechanism can reduce the production of or the responsiveness
to IFN-β and reduce the proinflammatory actions of AT mac-
rophages [8]. IFN-β is a member of the type I IFN family of
pleiotropic cytokines that is critical in the defence against viral
infections and able to modulate both innate and adaptive im-
munity [9]. IFN-α/β can exert their effects by binding to their
cognate receptor, the type I IFN receptor (IFNAR) complex,
which stimulates the Janus kinase (JAK) signal transducer and
activator of transcription (STAT) signalling pathway, leading
to the transcription of several IFN-stimulated genes [10].
While antibody-mediated neutralisation of IFN-β leads to a
decrease in the mRNA expression of proinflammatory genes,
including monocyte chemoattractant protein (MCP)-1, induc-
ible nitric oxide synthase and IL-6, recombinant IFN-β pro-
tein has the opposite effect [11]. In addition, IFN-β has been
reported to be necessary for maintaining the TLR-mediated
MCP-1 production in macrophages [12], facilitating the re-
cruitment of macrophages to sites of inflammation [13] and
modulating the inflammatory and metabolic effects of diet-
induced obesity (DIO) [14]. Thus, IFN-β induces a feedback
activation mechanism, thereby contributing to macrophage-
mediated inflammatory responses.
Type I IFNs are constitutively expressed in low quantities
by many tissues and cells of the body in the absence of viral
infection [15], supporting a potential physiological role of
IFN-α/β as the initial primers of immune function as a means
of maintaining immune homeostasis. A role has been pro-
posed for type I IFN in the activation of resident macrophages
and the recruitment of proinflammatory M1 macrophages to
the AT and liver during obesity.
Plasmacytoid DCs (pDCs) are a unique immune cell pop-
ulation involved in both innate and adaptive immunity. They
sense single-stranded RNA and microbial DNA through
endosomal TLR-7 and TLR-9, respectively, initiating a mye-
loid differentiation protein 88 (MyD88)-dependent signalling
cascade [16], leading to downstream activation of IRF7 and
robust type I IFN responses. The pDCs are responsible for the
vast majority of secreted type I IFN that promotes DC
maturation, natural killer cell-mediated cytotoxicity and Th1
differentiation, and plays a crucial role in protection against
viral and bacterial threats [16]. The induction and subsequent
nuclear relocation of the transcription factor IRF-7 is essential
for type I IFN expression in pDCs [17]. In comparison, DCs
and macrophages from IRF-7 knockout mice were still able to
produce normal levels of IFN-β [18].
Studies have shown that IRF-7 deficiency prevents DIO
and insulin resistance in mice [19], and that IRF-7 expression
is upregulated in the arteries of obese rats [20]. In addition,
murine gene expression analyses have reported significant
upregulation of IFN-α/β genes in both the visceral and sub-
cutaneous AT during obesity [21], suggesting a role for pDC-
derived type I IFN in obesity development. In support of this,
elevated frequencies of pDCs were observed in the liver and
AT of obese mice [4] and humans [22].
Here, we investigated whether DIO and the associated met-
abolic abnormalities are dependent on type I IFN signalling.
We also analysed pDC, the major type I IFN-producing cellu-
lar subset, activity accumulated in the liver and AT during
DIO and the effects of induced pDC deficiency on the devel-
opment of obesity and metabolic abnormalities. We
hypothesised that pDCs, through their IFN-producing capac-
ity, not only play significant roles in obesity-induced low-
grade inflammation and type 2 diabetes development but also
in the early stages of obesity development.
Methods
Animals C57BL/6 (B6) male mice were purchased from
Taconic (Ejby, Denmark). IFNAR−/− mice were kindly pro-
vided by B. Johansson-Lindbom, Lund University (Lund,
Sweden). B6.E2-2fl/fl mice were generated as previously de-
tailed [23] and B6.Cg-Tg(Itgax-cre)1-1Reiz/J mice were pur-
chased from Jackson Laboratory (Bar Harbor, ME, USA).
B6.E2-2fl/fl and B6.Cg-Tg(Itgax-cre)1-1Reiz/J mice were
paired; the offspring were screened for flox-sites and cre-
recombinase and were bred to produce the B6.E2-2fl/flItgax.cre+
and B6.E2-2fl/flItgax.cre− mice used in this study.
B6.E2-2fl/flItgax.cre mice were bred in a specific pathogen-
free animal facility at Lund University and kept under stan-
dard conditions with ad libitum access to water and food dur-
ing experiments. The experiments were conducted in compli-
ance with the National Institutes of Health guidelines, and all
animal experimental procedures were approved by the ethical
committee of Lund University Animal Care and Use.
Metabolic effects of DIO Themice weremaintained on either
a high-fat diet (HFD; 21.9 kJ/g [5.24 kcal/g], 34.9% (wt/wt)
fat, 26.2% (wt/wt) protein, 26.2% (wt/wt) carbohydrate;
D12492, Research Diets, New Brunswick, NJ, USA) or a
normal diet (ND; 12.6 kJ/g [3 kcal/g], 4% (wt/wt) fat, 18.5%
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(wt/wt) protein, 55.7% (wt/wt) carbohydrate; R36, Lactamin
AB, Stockholm, Sweden) for 18 weeks, starting at 5 weeks of
age.
Body weight was recorded weekly. For endpoint analysis,
the animals were fasted for 6 h before body composition scan-
ning using a GE-Lunar PIXImus 2 scanner (GE Healthcare,
Wauwatosa, WI, USA) or an OGTT, where blood glucose was
measured at various time points before and after oral glucose
administration (2 g/kg). Cheek blood samples were collected
before and after glucose administration for hormone analysis.
The mice were anaesthetised with Hypnorm/Dormicum
(Vetapharma, Leeds, UK/Roche, Basel, Switzerland) and
transcardially perfused with 15 ml PBS, followed by dissec-
tion of subcutaneous white adipose tissue (SAT), visceral
white adipose tissue (VAT), brown adipose tissue (BAT), the
spleen and the liver for flow cytometry.
Flow cytometric analysis Single cell suspensions from the
spleen were obtained by disrupting the tissue through a 70 μm
cell strainer. The livers were mechanically minced into small
>1 mm pieces, washed twice in PBS, treated with collagenase
II (Invitrogen, Carlsbad, CA, USA) for 40 min at 37°C, and
single cells were suspended through a 70 μm cell strainer and
separated by 50/30 Percoll (GE Healthcare) gradient centrifu-
gation. The white adipose tissue samples were mechanically
minced and collagenase II digestion was performed for 40min
at 37°C to fractionate the AT into adipocytes and a stromal
vascular fraction (SVF). The SVF was resuspended in
HEPES-buffered RPMI medium (Gibco, Waltham, MA,
USA) and single cells were suspended through a 70 μm cell
strainer. All samples were resuspended in FACS buffer (PBS,
3% [vol./vol.] FCS, 2 mmol/l EDTA) prior to surface staining,
preincubated with anti-CD16/32 (Fc ‘blocking’ antibody,
clone 2.4G2) (BD Biosciences, San Jose, CA, USA) for
15 min at 4°C and subsequently stained with fluorescent-
labelled primary antibodies for 25 min at 4°C. The following
antibodies were used: anti-TCRβ (clone H57-597) and anti-
SiglecF (clone E50-2440) from BD Biosciences; anti-CD317
(clone 120G8.04) from Dendritics (Lyon, France); anti-Ly6G
(clone 1A8), anti-Ly6C (clone HK1.4), anti-NK1.1 (clone
PK136), anti-CD45 (clone 30-F11), anti-I-A/I-E (clone M5/
114.15.2), anti-CD11b (clone M1/70) and anti-CD206 (clone
C068C2) from Biolegend (San Diego, CA, USA); and anti-
CD4 (clone GK1.5), anti-F4/80 (clone BM8), anti-
CD45R(B220) (clone RA3-6B2), anti-CD8 (clone 53-6.7),
anti-CD11c (clone N418), anti-SiglecH (clone 440c), anti-
CD19 (clone 1D3) and fixable viability dye (FVD) from
eBioscience (Santa Clara, CA, USA). The cells were fixed
using the Foxp3 Staining Buffer Set (eBioscience). Samples
containing biotin-coupled antibodies were incubated for
25min at 4°C with secondary Streptavidin-PECF594 antibod-
ies (BD Biosciences). Cells were washed twice in FACS buff-
er and data acquisition was performed on a BD LSR II flow
cytometer with FACSDiva software (BD Biosciences). A
minimum of 50,000 CD45+ events were analysed for each
sample. The analysis was performed using the FlowJo soft-
ware (FlowJo LLC, Ashland, OR, USA).
Insulin ELISA Cheek blood samples were collected from
mice as a part of the OGTT, and plasma was isolated with
the aid of EDTA-K tubes (Sarstedt, Nümbrecht, Germany).
The tubes were spun at 1000× g for 15 min to isolate plasma.
Insulin levels were analysed using an Ultra Sensitive Mouse
Insulin ELISA kit (CrystalChem, Downers Grove, IL, USA).
Statistical analysis Pairwise group comparison was per-
formed using unpaired two-tailed Student’s t test or two-way
ANOVA using GraphPad Prism 5 (GraphPad Software, San
Diego, CA, USA). The values are presented as the mean ± SD.
Results
Development of DIO and insulin resistance is dependent
on type I IFN signallingTo gain insight into the potential role
of type I IFN in obesity and obesity-related metabolic abnor-
malities, we used the HFD mouse model of type 2 diabetes.
From 5 weeks of age, male C57BL/6 (B6) mice were given ad
libitum access to either an HFD or ND for 18 weeks. As
shown before [24], mice fed an HFD showed a significant
weight increase of 64% compared with ND-fed littermates
(Fig. 1a). At the 18 week endpoint, the obese mice had devel-
oped glucose intolerance and insulin resistance (Fig. 1b, c).
The detrimental stage of metabolic disease was evident by the
increase in the sizes of the fat pads and the liver, which were
significantly enlarged in obese mice (HFD, 2.35 ± 0.29 g; ND,
1.10 ± 0.16 g) (Fig. 1d). Using an x-ray densitometer, lean and
fat mass was compared between the two groups, by which the
difference in weight gain was attributed to a significant in-
crease in fat mass (Fig. 1e, f).
To directly test the hypothesis that type I IFN plays a sig-
nificant role in the development of obesity and type 2
diabetes-related metabolic abnormalities, we exposed mice
lacking the receptor for IFN-α (IFNAR−/−) to an HFD. In
support of the hypothesis, we found that the HFD-fed
IFNAR−/− mice displayed a relative resistance to diet-
induced weight gain compared with the B6 control mice on
anHFD (Fig. 1g). This differencewas significant after 6weeks
following the initiation of HFD feeding. At the endpoint after
18 weeks of HFD, the IFNAR−/−mice had an 11% lower body
weight compared with the control B6 mice (IFNAR−/−HFD
44.7 g vs B6 HFD 49.9 g). This was associated with signifi-
cantly smaller subcutaneous fat depots and a lower total fat
mass in the HFD-fed IFNAR−/−mice compared with B6 mice
(Fig. 1f, h).
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DIO led to elevated numbers of proinflammatory macro-
phages in AT which are reduced in absence of IFNAR1
Obese mice developed a low-grade inflammation in the vis-
ceral fat deposits, with an increased number of leucocytes and
an altered immune cell repertoire characterised by elevated
levels of CD11c+ proinf lammatory macrophages
(CD11c+CD11b+F4/80+) (Fig. 2a–d).
When examining the infiltrating cell population in the in-
flamed AT, we found an expectedly large proportion of the
CD11c+ cells to be proinflammatory macrophages (F4/
80+CD11b+CD11c+) (Fig. 2b–d). In the liver the number of
proinflammatory macrophages was also found to be signifi-
cantly increased (Fig. 2c). When applying a subsequent
analysis of the total CD11c+ population in the liver, we found
significantly higher numbers in the obese state but also noted
that a large proportion of these cells could not be accounted
for by the macrophage population (Fig. 2c).
To determine whether the metabolic effects observed in the
absence of type I IFN signalling were linked to a decreased
inflammation in VAT and the liver we exposed the IFNAR−/−
mice and B6 control mice to an 18 week period of HFD
feeding and compared them to groups fed an ND (Fig. 2e–
g). We observed that the accumulation of proinflammatory
macrophages in VAT of B6 mice was reduced in the absence
of IFNAR1 (Fig. 2g). This would be in line with a previously
suggested role of IFN-I in proinflammatory polarisation of
VAT-recruited macrophages [22].
DIO led to elevated numbers of pDCs Because it has been
previously reported that pDCs increase in both the liver and
AT of HFD-treated animals [4], we hypothesised that this DC
subset could account for the observed increase in CD11c+
cells in the liver. We therefore identified the pDCs among
the CD11c+ population by gating away B cells (CD19+),
Fig. 1 Characteristics and metabolic profile of B6 and IFNAR−/− male
mice exposed to ND or HFD. Mice were given an ND or HFD for
18 weeks, starting at 5 weeks of age. (a) Weekly weight measurements
of the B6 mice fed an ND (white circles) or HFD (black circles). (b) An
OGTTwas performed after 18 weeks. B6mice were given an oral dose of
glucose and blood glucose was determined from tail vein samples at
different time points. ND, white circles; HFD, black circles. (c) Fasting
insulin levels in ND- or HFD-fed B6 mice. (d) Individual tissue weights
from B6mice after 18 weeks. ND, white bars; HFD, black bars. (e) Image
of an x-ray scan determining the fat content in B6 and IFNAR−/− mice
after 18weeks on anND or HFD. (f) Proportion of fat in B6 and IFNAR−/−
mice after 18 weeks of an ND or HFD determined by x-ray scanning. (g)
Weekly weight measurements of the IFNAR−/− (squares) and control B6
(circles) mice fed an ND (white symbols) or HFD (black symbols). A
significant difference was only indicated for B6 mice on an HFD. (h)
Individual tissue weights of IFNAR−/− and B6 mice after 18 weeks. (f, h)
IFNAR−/− ND, light grey bars; IFNAR−/− HFD, dark grey bars; B6 ND,
white bars; B6 HFD, black bars. n = 6 for ND- and n = 18 for HFD-fed
animals, except for in (b, c) where n = 6 for ND- and HFD-fed animals.
The experiments were repeated independently 2–3 times. *p ≤ 0.05,
**p ≤ 0.01, ***p ≤ 0.001 using two-way ANOVA (a, b, f, g, h) or
Student’s t test (c, d)
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natural killer cells (NK1.1+) and macrophages (F4/80+ and
CD11b+) and focusing on the B220+120G8+CD11c(int) subset
(Fig. 2h–j). While the expression of the pDC marker Siglec-H
was high in the splenic pDC population, the same subset in the
liver and fat depots demonstrated variable expression profiles
(Fig. 2k); the marker itself was also recently found to be less
specific than initially proposed [25] and is partly sensitive to
collagenase treatment [26]. The 120G8 antibody specifically
targets BST-2 and constitutes a suitable marker for pDCs, as
illustrated by its ability to eliminate pDCs through antibody
depletion without significantly affecting other cell populations
[27]. Using this gating strategy, we found that the pDC pop-
ulation was significantly increased in both the liver and VAT
after HFD feeding (a 2.7-fold increase in the liver and 4.3-fold
increase in VAT), and was most abundant in the liver (Fig. 2j).
In the liver, pDCs accounted for almost 50% of the CD11c+
population in the obese group and approximately 30% in the
lean group (Fig. 2h–j).
pDC deficiency protects against weight gain The observed
accumulation of pDCs in both the liver and AT, as well as the
protection from obesity development in the IFNAR knockout
mice, suggest that this cellular subset could play a role in the
pathology observed in the DIOmodel. To directly address this
issue, we used the B6.E2-2fl/fl.Itgax-cre mouse strain, in which
the conditional knockout of E2-2 results in a specific block of
the development of pDCs [23] (Fig. 3). A pronounced de-
crease in this subset is evident in both the bone marrow [23]
and peripheral organs, including the spleen, liver and AT
(Fig. 3a, b). In contrast, no significant alteration was seen in
other haematopoietic subsets, such as macrophages and DCs
(Fig. 3c–e).
Fig. 2 DIO promotes proinflammatory macrophage and pDC infiltration
in the ATand liver. Flow cytometry analysis of leucocytes from the spleen
and liver and SVF from the VAT of lean (white bars) and obese (black
bars) B6 mice or lean (light grey bars) and obese (dark grey bars)
IFNAR−/− mice. (a) Number of live CD45+ cells. (b) Representative
contour plots of FVD−CD45+CD11c+F4/80+CD11b+ cells from the liver
or VAT of lean (ND) and obese (HFD) B6 mice with the gating for the
proinflammatory macrophage subset of total CD45+ cells shown. (c)
Number and (d) percentage of FVD−CD45+CD11c+F4/80+CD11b+ pro-
inflammatory macrophages out of CD45+ cells. (e) Number of live
CD45+ cells. (f) Percentage of total FVD−CD45+CD11b+F4/80+
macrophages out of l ive CD45+ cel ls . (g) Percentage of
FVD−CD45+CD11c+F4/80+CD11b+ proinflammatory macrophages out
of l ive CD45+ cells. (h) Representative contour plots of
FVD−CD45+CD19−B220+120G8+CD11cint cells from the liver or VAT
of lean (ND) and obese (HFD) B6 mice with the gating for the pDC
subset of total live CD45+ cells shown. (i) Number and (j) percentage
of pDCs out of live CD45+ cells. (k) Representative contour plots of
FVD−CD45+CD19−B220+CD11cint cells showing the expression of
Siglec-H and 120G8. n = 6 in all groups of animals. The experiments
were repeated independently at least 2 times. *p ≤ 0.05, **p ≤ 0.01,
***p ≤ 0.001 using Student’s t test. MΦ, macrophage
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Next we exposed E2-2 conditional knockout (E2-2.cre+)
mice and control littermates (E2-2.cre−) to an 18 week period
of HFD feeding and compared them to groups fed an ND. As
with the IFNAR−/−mice, we observed a significant difference
in weight gain between the E2-2.cre+ and the E2-2.cre−
groups, with a significantly lower weight gain in the E2-
2.cre+ mice (45.6 g for E2-2.cre+ and 54.4 g for E2-2.cre−mice)
that was evident from as early as week 4 on an HFD (Fig. 4a).
The reduced weight gain was accompanied by increased insu-
lin sensitivity (Fig. 4b). Thus, while the control group at the
endpoint had reached the level of insulin resistance, the E2-
2.cre+ mice were protected from developing insulin resistance
(Fig. 4b). An improved, albeit not significant, GTT was also
noted (Fig. 4c).
Interruption of type I IFN signalling and pDC deficiency
prevents DIO and insulin resistance by affecting energy
metabolism To investigate if the observed protection from
weight gain among the IFNAR−/− mice was the result of a
decrease in energy intake or energy expenditure, we registered
the food intake throughout the experiment. As illustrated in
Fig. 5a, no significant difference between the IFNAR−/− and
B6 mice was observed at any time point, suggesting that the
observed difference in weight gain was due to different energy
expenditure. Similarly, when the metabolic differences be-
tween E2-2.cre+ and E2-2.cre− mice were assessed through
their food intake, no significant difference was observed
(Fig. 5b). Additionally, when assessing the mice, which were
kept in groups of 4–6 individuals, no differences in behavioural
patterns were seen between the groups. These results suggest that
the ablation of type I IFN signalling, as well as pDC deficiency,
prevented the mice from developing DIO and insulin resistance
by affecting energy metabolism.
Discussion
In the current study, we present evidence that type I IFN plays a
critical role in the development of obesity and diabetes in the
DIO mouse model of type 2 diabetes. Using IFNAR−/− mice,
we demonstrated that the absence of type I IFN signalling
protected them from the development of DIO and diabetes.
Since pDCs, a major source of type I IFN [16, 28], have been
reported to accumulate in the ATand liver of obese mice [4], we
reasoned that this cellular subset could constitute a key compo-
nent in the type I IFN-mediated infiltration of proinflammatory
M1 macrophages during obesity development. In agreement
with this hypothesis, we demonstrated that pDC-deficient E2-
2.cre+ mice displayed a similar resistance to developing DIO
and insulin resistance as observed in IFNAR−/− mice.
Type I IFNs are prominent in viral infections, where they
promote host defence mechanisms. However, a role of the
Fig. 3 Significant reduction in pDCs in the E2-2.cre+ mouse. Flow cytom-
etry analysis of CD45+ leukocytes from the spleen and liver and SVF from
theVATandSATof E2-2.cre+ andE2-2.cre−mice. (a) Representative contour
plots of FVD−CD45+CD19−B220+120G8+CD11cint cells with gating for
pDCs. Percentages of (b) pDCs and (c) total FVD−CD45+CD11b+F4/80+
macrophages. (d) FVD−CD45+CD11c+F4/80+CD11b+ proinflammatory
macrophages. (e) FVD−CD45+CD11chiCD11b−MHCII+ DCs and in the
spleen, liver, VAT and SAT of E2-2.cre+ (black bars) and E2-2.cre− (white
bars) mice. (b–e). n = 6 in eachmouse group. The experiments were repeated
independently at least 2 times. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001 using
Student’s t test. MΦ, macrophage
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pleiotropic cytokine family in several biological processes has
also been proposed [8, 11]. Type I IFNs have previously been
indirectly implicated in obesity development based on the
analysis of the IRF-7−/−mouse [19]. IRF-7 plays an important
role in innate immunity through the regulation of IFN-α/β
secretion. These IFNs can further activate cells through inter-
actions with IFNAR, thereby inducing additional IRF-7 ex-
pression, which is required for the type I IFN positive feed-
back loop. A study by Wang et al [19] suggests that improved
energy expenditure protects IRF-7−/− mice from developing
DIO. In agreement with their findings, our data suggest that
the protection from weight gain in the absence of type I IFN
signalling is a consequence of altered immune–metabolism
interplay, resulting in increased energy metabolism. This is
in line with the notion that the immune system may play an
important role in maintaining energy balance.
The pDCs are professional type I IFN producers responsi-
ble for the vast majority of IFN-α/β secretion [29]. While
pDCs are most well-known for their antiviral activity and
ability to secrete vast amounts of IFN-I in response to TLR
recognition of double-stranded RNA and CpG motifs, these
cells have also been implicated in several disease conditions
associated with systemic inflammation, including autoim-
mune diabetes [30, 31]. An abundance of nucleic acid ligands
and a critical role of TLR-9 in obesity-associated inflamma-
tion has also been reported previously both in animal models
and humans [22, 32–35]. The finding that IFNAR−/−mice are
protected from DIO highlights a possible role of pDCs in
obesity-associated inflammation. While the pDCs have previ-
ously been found at an elevated frequency in the AT and liver
of obese mice [4], human studies have found decreased
[36–38] or unaltered [30, 39] numbers of circulating pDCs
in obese individuals with type 2 diabetes compared with lean
individuals but have been unable to investigate the possible
relocation of these cells. The data obtained from the analysis
of the mouse model of DIO reported here and previously by
Stefanovic-Racic et al [4] supports the notion of a recruitment
and activation of pDCs in obese VAT possibly, as has been
previously suggested, mediated by the adipokine chemerin
[22, 40]. However, in light of conflicting results [6], further
studies are needed in order to elucidate this possibility.
The accumulation of pDCs in the liver during obesity de-
velopment may suggest a role of this subset in this organ.
Similar to the AT, the accumulation of pDCs in the liver was
correlated with an increase in the number of proinflammatory
macrophages. Even at steady state, pDCs are highly abundant
in the liver, accounting for one-third of the DC population.
Fig. 4 Characteristics and metabolic profile of E2-2.cre+ and E2-2.cre−
mice on ND or HFD. Mice were fed either an ND or HFD for 18 weeks,
starting at 5 weeks of age. (a) Weekly weight measurements of the four
groups of mice (n = 8 for ND and n = 12 for HFD): E2-2.cre+ND (white
triangles) E2-2.cre+ HFD (black triangles), E2-2.cre− ND (white circles),
E2-2.cre−HFD (black circles). (b) Fasting insulin levels for HFD-fed E2-
2.cre+ (white bar) and E2-2.cre− (black bar) mice. (c) An OGTT
performed after 18 weeks (n = 6). Mice were given an oral dose of
glucose (2 g/kg) and blood glucose was determined from tail vein sam-
ples at different time points. E2-2.cre+ HFD (black triangles), E2-2.cre−
HFD (black circles). The experiments were repeated independently 2–3
times. **p ≤ 0.01, ***p ≤ 0.001 using two-way ANOVA (a, c) or
Student’s t test (b)
Fig. 5 Food intake of E2-2.cre+ and IFNAR−/− mice is unaltered com-
pared with control mice. Food intake per cage for (a) IFNAR−/− (dashed
grey line) and B6 mice (black line) and (b) E2-2.cre+ (dashed grey line)
and E2-2.cre− (black line) littermates. n = 2–6 cages, n = 6 animals per
cage. Two-way ANOVA was used; no significant differences were
observed
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While the precise reason for this accumulation is unknown, it
is likely to be part of the requirement for the optimal defence
mechanisms of the liver, as it encounters an array of sub-
stances through processed blood from the gastrointestinal
tract. This includes gut-derived commensal bacterial products
[41, 42], of which the composition is affected by what is
ingested. As pDCs are known to play an important role in
the defence against invadingmicrobes, it is plausible that even
a swift change in the nutrient composition could induce their
TLR-mediated production of proinflammatory cytokines [43].
Indeed, studies have shown that the gut microbiome rapidly
responds to dietary changes in both humans [44] andmice [45,
46], which has been proposed to contribute to obesity.
To directly address the pDCs as possible mediators of obe-
sity development through their type I IFN-producing ability,
we used a mouse with a conditional knockout of E2-2, the E2-
2.cre+ mouse, resulting in a specific block in the development
of pDCs [23]. We found that these mice were protected from
DIO development, comparable to the IFNAR−/− mice. In ad-
dition, the mice were also protected from developing insulin
resistance and showed mildly improved glucose tolerance.
Taken together, our results suggest a key role for pDC-
derived type I IFN in obesity development. This concurs with,
and gives genetic evidence for, a model recently presented by
Ghosh et al [22] suggesting that low-grade inflammation as-
sociated with obesity is driven by type 1 IFN produced by
pDCs recruited to VAT and leading to proinflammatory
polarisation of adipose-resident macrophages.
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